Signes-Costa, 5,847 patient HCQ late treatment study: 47% lower mortality [p=0.0005] https://c19p.org/signescosta
copied to clipboard
Prevalence and 30-day mortality in hospitalized patients with COVID-19 and prior lung diseases
et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.11.012
47% lower mortality with HCQ/CQ. Retrospective 1,271 patients with lung disease in Canada, China, Cuba, Ecuador, Germany, Italy and Spain, 83% treated with HCQ/CQ.Multivariable Cox regression HCQ/CQ mortality hazard ratio HR 0.53, p < 0.001.
|
risk of death, 47.0% lower, RR 0.53, p < 0.001, treatment 4,854, control 993, adjusted per study.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Signes-Costa et al., 12/16/2020, retrospective, multiple countries, multiple regions, peer-reviewed, 28 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.